ADC Therapeutics SA ADCT.N, ADCT.K is expected to show a rise in quarterly revenue when it reports results on March 10 (estimated) for the period ending December 31 2024
The Epalinges Vaud-based company is expected to report a 13.2% increase in revenue to $19.006 million from $16.79 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
LSEG's mean analyst estimate for ADC Therapeutics SA is for a loss of 42 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for ADC Therapeutics SA is $9.00, above its last closing price of $1.75.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.36 | -0.39 | -0.42 | Missed | -6.3 |
Jun. 30 2024 | -0.45 | -0.46 | -0.38 | Beat | 16.9 |
Mar. 31 2024 | -0.55 | -0.56 | -0.56 | Met | -0.8 |
Dec. 31 2023 | -0.48 | -0.50 | -1.03 | Missed | -104.8 |
Sep. 30 2023 | -0.65 | -0.63 | -0.58 | Beat | 8.5 |
Jun. 30 2023 | -0.35 | -0.46 | -0.58 | Missed | -26.9 |
Mar. 31 2023 | -0.76 | -0.67 | -0.74 | Missed | -10.4 |
Dec. 31 2022 | -0.21 | -0.29 | -0.30 | Missed | -4.6 |
This summary was machine generated March 7 at 13:05 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。